Riskpilot← Back to searchSign inGet full accessPHARMASUM THERAPEUTICS AS
ASActiveOrg 913746430Sharelab Forskningsparken I Oslo Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20143 employeeswww.pharmasum.com
Revenue 2024
NOK 990K
-28% vs 2023
EBITDA margin
-285.0%
-95% vs 2023
Equity ratio
-1.7%
Financial strength
Net profit 2024
NOK -2,8M
-61% vs 2023
| Revenue | NOK 990K | -28% |
| EBITDA | NOK -2,8M | -95% |
| Net profit | NOK -2,8M | -61% |
| Total assets | NOK 1,5M | -70% |
| Equity | NOK -26K | -101% |
| Employees | 3 | — |
Legal name
PHARMASUM THERAPEUTICS AS
Org number
913746430
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17. juni 2014
Share capital
NOK 322 672
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikling, markedsføring, fremstilling/salg av farmasøytiske og bioteknologiske produkter og andre produkter som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender.
Address
Sharelab Forskningsparken I Oslo Gaustadalléen 21, 0349 Oslo
Website
www.pharmasum.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 538 | 1 520 | 1 380 | 990 |
| Staff expenses | −68 | −1 668 | −1 982 | −1 912 | −1 519 |
| EBITDA | −518 | −3 239 | −2 176 | −1 444 | −2 821 |
| Depreciation & amort. | −0 | −0 | −10 | −13 | −13 |
| EBIT | −518 | −3 239 | −2 186 | −1 457 | −2 834 |
| Net financials | −94 | −9 | −1 | −294 | 23 |
| Profit before tax | −612 | −3 248 | −2 187 | −1 751 | −2 811 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −612 | −3 248 | −2 187 | −1 751 | −2 811 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 206 | 3 471 | 1 424 | 5 180 | 1 535 |
| Equity | 2 908 | 1 298 | −889 | 2 785 | −26 |
| Long-term debt | 0 | 1 323 | 1 323 | 1 068 | 1 068 |
| Short-term debt | 2 298 | 850 | 990 | 1 326 | 492 |
| Total debt | 2 298 | 2 173 | 2 313 | 2 395 | 1 560 |
EBITDA margin
-285.0%
This company
15.8%
Market median
-1904% vs market
20202024
Equity ratio
-1.7%
This company
38.2%
Market median
-104% vs market
20202024
Return on equity
-281089700.0%
This company
18.4%
Market median
-1527661513% vs market
20202024
Net profit margin
-284.0%
This company
8.1%
Market median
-3606% vs market
20202024
Asset turnover
0.65×
This company
1.12×
Market median
-42% vs market
20202024
Debt / equity
61.00×
This company
0.62×
Market median
-9739% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2024 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Chairman | 2019 – 2021 | |
| Board of Directors | 2019 – 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 15.32% | 15.32% | 2024 | |
| Company | 13.1% | 13.1% | 2024 | |
| Company | 8.16% | 8.16% | 2024 | |
| Company | 7.9% | 7.9% | 2024 | |
| Company | 3.27% | 3.27% | 2024 | |
| Individual | 3.04% | 3.04% | 2024 | |
| Company | 2.43% | 2.43% | 2024 | |
| Company | 2.15% | 2.15% | 2024 | |
| Company | 2.13% | 2.13% | 2024 | |
| Individual | 2.04% | 2.04% | 2022 | |
| Company | 2.01% | 2.01% | 2024 | |
| Individual | 1.84% | 1.84% | 2024 | |
| Individual | 1.45% | 1.45% | 2022 | |
O2h Venture Ltd | Company | 1.32% | 1.32% | 2024 |
| Individual | 1.32% | 1.32% | 2024 | |
| Company | 1.19% | 1.19% | 2024 | |
| Company | 1.17% | 1.17% | 2024 | |
| Company | 1.14% | 1.14% | 2024 | |
| Company | 1.09% | 1.09% | 2024 | |
| Individual | 1.05% | 1.05% | 2024 | |
| Individual | 1.01% | 1.01% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fugelli Invest As
PHARMASUM THERAPEUTICS AS Board members of PHARMASUM THERAPEUTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Sigurd Mjøen Svendsen | Board of Directors | 0 companies |
| Øystein Soug | Board of Directors | 0 companies |
| Andrew Alexander Parsons | Chairman | 0 companies |
| Tone Bjørnov | Board of Directors | 0 companies |
| Reijo Juhani Salonen | Board of Directors | 0 companies |
| Masha Paule Nathalie Legris Strømme | Board of Directors | 0 companies |